A revolutionary innovation in the personalized medicine space was introduced by the expert research team at the Huntsman Cancer Institute at the University of Utah. The team successfully calibrated, developed, and demonstrated a tool for recognizing the changes in genes of Lynch syndrome that are expected to cause the disease symptoms. Lynch syndrome condition results in increased rates of endometrial, colon and other types of cancers. With numerous distinct changes that are probable to occur in genes that impact health, recognizing specific changes which are related to growing diseases becomes crucial. While certain genetic transformations are not impactful, some could carry significant risks. The Huntsman Cancer Institute research team work to comprehend and distinguish which changes in the gene are likely to cause disease and recognize the suitable strategies for managing the disease risk.
Sean Tavtigian, a researcher at Huntsman Cancer Institute and professor of oncology sciences at the University of Utah, led the break-through research study. Tavtigian stated that it is fundamentally crucial to identify which gene changes observed by them result in disease. Tavtigian further added that by gaining a clear picture of this factor has the ability to reduce disease-related anxiety, increase the lifespan of patients and use the healthcare revenue efficiently.
An Effective Analytical Tool for Identifying Gene Changes
A laboratory test called the Cell-free in vitro MMR Activity (CIMRA) assay which was previously designed by the group of Niels de Wind, the human genetics professor at The Netherlands’ Leiden University Medical Center for characterizing genetic changes related to disease risk, was used by this team of researchers. This lab test is accurate and rapid and enhances the variant classification of doubtful vitality in Lynch syndrome. This lab test was deeply verified and calibrated in the current research study so that the results could be integrated with clinical data and computer-based modelling, owing to which it provides an analytic tool appropriate for clinical use for evaluating changes in Lynch syndrome genes.
Breakthrough Solution: Personalized Medicine Tool
It is indicated that the nearly five percent of all colorectal cancer cases are related to the Lynch syndrome. With the innovative personalized medicine tool introduced by these researchers for inherited colorectal cancer syndrome would bring new transformations to the personalized medicine market. As stated in the personalized medicine market research study provided by Future Market Insights, personalized medicines are attracting major attention presently owing to the effectiveness in patients suffering from cancer or other rare genetic disorders. To gain more insights related to the potential held by the market and the key developments carried out by the prominent market players, click here.